Clinical multidrug resistance ( MDR ) of malignancies to many antineoplasticagents is the major obstacle in the successful treatment of cancer. The emergence of breast cancerresistance protein ( BCRP), a member of the...Clinical multidrug resistance ( MDR ) of malignancies to many antineoplasticagents is the major obstacle in the successful treatment of cancer. The emergence of breast cancerresistance protein ( BCRP), a member of the adenosine triphosphate ( ATP ) binding cassette ( ABC )transporter family, has necessitated the development of antagonists. To overcome the BCRP-mediatedatypical MDR, RNA interference (RNAi) delivered by adenovirus targeting BCRP mRNA was used toinhibit the atypical MDR expression by infecting MCF-7/MX100 cell lines with constructed RNAiadenovirus.展开更多
文摘Clinical multidrug resistance ( MDR ) of malignancies to many antineoplasticagents is the major obstacle in the successful treatment of cancer. The emergence of breast cancerresistance protein ( BCRP), a member of the adenosine triphosphate ( ATP ) binding cassette ( ABC )transporter family, has necessitated the development of antagonists. To overcome the BCRP-mediatedatypical MDR, RNA interference (RNAi) delivered by adenovirus targeting BCRP mRNA was used toinhibit the atypical MDR expression by infecting MCF-7/MX100 cell lines with constructed RNAiadenovirus.
